UY38145A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents

Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Info

Publication number
UY38145A
UY38145A UY38145A UY38145A UY38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A
Authority
UY
Uruguay
Prior art keywords
stimulator
cyclopentane
interferon genes
sting modulators
compounds
Prior art date
Application number
UY38145A
Other languages
English (en)
Inventor
Mehran Jalaie
Martin James Wythes
Andrew Fensome
Ryan Patman
Andreas Maderna
Ketan S Gajiwala
Indrawan James Mcalpine
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY38145A publication Critical patent/UY38145A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de la fórmula general (I): o una sal farmacéuticamente aceptable del mismo, procesos para la preparación de estos compuestos, composiciones que contiene estos compuestos, y los usos de estos compuestos.
UY38145A 2018-03-15 2019-03-13 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano UY38145A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25

Publications (1)

Publication Number Publication Date
UY38145A true UY38145A (es) 2019-10-31

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38145A UY38145A (es) 2018-03-15 2019-03-13 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Country Status (24)

Country Link
US (4) US10538542B2 (es)
EP (1) EP3765474B1 (es)
JP (1) JP7266942B2 (es)
KR (1) KR20200131878A (es)
CN (1) CN111918871A (es)
AU (1) AU2019234043A1 (es)
BR (1) BR112020018593A2 (es)
CA (1) CA3093631C (es)
CL (1) CL2020002352A1 (es)
CR (1) CR20200382A (es)
DO (1) DOP2020000160A (es)
EC (1) ECSP20057847A (es)
ES (1) ES2923298T3 (es)
IL (1) IL277278A (es)
MA (1) MA52012A (es)
MX (1) MX2020009587A (es)
NI (1) NI202000058A (es)
PE (1) PE20210412A1 (es)
PH (1) PH12020551486A1 (es)
RU (1) RU2020130048A (es)
SG (1) SG11202008102VA (es)
TW (1) TWI741268B (es)
UY (1) UY38145A (es)
WO (1) WO2019175776A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
BR112022005463A2 (pt) * 2019-09-25 2022-06-14 Pfizer Moduladores poli-heterocíclicos de sting (estimulador de genes de interferon)
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP6462006B2 (ja) * 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑(sting)的環戊烷為主體之調節劑

Also Published As

Publication number Publication date
CA3093631A1 (en) 2019-09-19
US10968242B2 (en) 2021-04-06
JP7266942B2 (ja) 2023-05-01
CA3093631C (en) 2023-01-24
US20190284216A1 (en) 2019-09-19
US10538542B2 (en) 2020-01-21
US20210230196A1 (en) 2021-07-29
BR112020018593A2 (pt) 2020-12-29
TW201945036A (zh) 2019-12-01
CR20200382A (es) 2020-12-10
MA52012A (fr) 2021-01-20
RU2020130048A3 (es) 2022-04-15
US20200102334A1 (en) 2020-04-02
MX2020009587A (es) 2020-10-05
TWI741268B (zh) 2021-10-01
JP2021518335A (ja) 2021-08-02
PE20210412A1 (es) 2021-03-04
EP3765474A1 (en) 2021-01-20
SG11202008102VA (en) 2020-09-29
US20230382932A1 (en) 2023-11-30
IL277278A (en) 2020-10-29
EP3765474B1 (en) 2022-06-15
ES2923298T3 (es) 2022-09-26
AU2019234043A1 (en) 2020-09-17
KR20200131878A (ko) 2020-11-24
DOP2020000160A (es) 2020-09-30
NI202000058A (es) 2021-01-08
PH12020551486A1 (en) 2021-08-23
CL2020002352A1 (es) 2020-12-18
ECSP20057847A (es) 2021-04-29
CN111918871A (zh) 2020-11-10
RU2020130048A (ru) 2022-04-15
WO2019175776A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2020001220A2 (es) Compuestos, composiciones y métodos
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2021002104A1 (es) Compuestos, composiciones y métodos.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
UY35362A (es) Compuestos terapéuticos
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY37941A (es) Derivados de bencimidazol y sus usos
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
EA202091913A1 (ru) Модуляторы sting (стимулятора генов интерферона) на основе циклопентана
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
AR105924A1 (es) Compuestos terapéuticos y síntesis
AR102887A1 (es) Una triazolopiridazina como modulador de quinasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240513